Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Scientists from two departments within University of Oxford Medical Sciences Division have been awarded research grants by the British Medical Association.

Dr Lynda Coughlan (left) and Dr Jeremy Howick (right) receiving their awards
Dr Lynda Coughlan (left), BMA President, Professor Pali Hungin (centre) and Dr Jeremy Howick (right)

Dr Jeremy Howick and Prof Paul Nicholas Aveyard from Nuffield Department of Primary Care Health Sciences were awarded the Dawkins & Strutt grant of almost £60,000 to support pioneering research into pain treatment. The HC Roscoe grant of £50,000 was awarded to Jenner Institute scientists from Nuffield Department of Medicine, Dr Lynda Coughlan and Prof Adrian Hill, who will use the funding to develop improved vaccines for influenza and other emerging infectious diseases.

The work of the BMA Foundation continues to be a success, and each year we fund important, innovative projects to advance medical research. With research funding budgets constrained, we want to support and encourage the medical profession in pursuing high-quality research projects that deliver important improvements in patient care. - Dr Mark Porter, BMA council chair and chair of the foundation trustees commenting on the awards

Fifteen medical academics and research scientists were awarded a total of £500,000 at this year’s prestigious BMA Foundation for Medical Research Awards on Tuesday 22 November. The awards were presented by BMA President, Professor Pali Hungin.

The BMA was one of the first professional bodies to award grants and prizes, with the aim of encouraging and furthering medical research. These grants fund basic and clinical medical research, covering a diverse range of research areas including pain treatment, viral infection and cancer. The BMA Foundation for Medical Research Awards has had a significant impact on the professional development of grant winners, with 96 per cent of previous winning researchers saying that being awarded the grant contributed to their future research. 

Commenting on her award, Dr Coughlan said: “As an early-career researcher starting to establish independence, this grant will have a huge impact on my future careerExosomes are a new and exciting breakthrough in health-innovation and we hope that support of this research will lead to the development of improved vaccines for infectious disease in the near future”.

Dr. Howick commented: “This award will generate the evidence base required for a research programme that promises to tackle the growing problem with too much medicine in the growing ageing population that suffers from pain

Links

Similar stories

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.

RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Major new study could help protect millions of people with type 2 diabetes from cardiovascular disease

A new study led by the Nuffield Department of Population Health at the University of Oxford will research whether a daily tablet could help protect the millions of people worldwide with type 2 diabetes from developing cardiovascular disease.